1) Laughable Market Cap of $69 M
2) Cash for 12 Months ....... Profitability before Year End
3) 3 Products launched in USA since December 2012
4) Fourth Product will enter the Market in this Quarter
5) 11 Products under review by FDA many of these will get FDA approval within 12 Months
6) Another 3 ANDA filings coming before year end
7) 68% of all Shares Outstanding held by Insiders & Institutions and still buying more
8) Small Float of only ~12 Million Shares

I think targets of $8-12 within 1-2 years is more realistic than Roth Capitals $3.50 .

Ticker ( IG )

Market Cap : $69 M
Cash : $1.3 M
Price : $1.60

Shares Out : 43 M
Float : 12 M

Roth starts IGI Labs at buy
August 7, 2013

Roth Capital Partners has initiated coverage of IGI Laboratories (NYSE MKT:IG) with a “buy” rating and 12-month price target of $3.50, saying the impetus for the rating is “expectations for the company’s internal proprietary generic pipeline to come to fruition and drive sustainable earnings profitability.”

Analyst Scott Henry writes that IGI Labs has 11 ANDAs at the FDA, and “we expect approvals starting in late 2013/early 2014. We view this pipeline as the engine for sustainable profitability in 2014-plus.”

In addition, he said IGI is currently launching two new products – Synalar and econazole nitrate – that could have combined annual peak revenue potential approaching $10-million. These compounds could take the company to earnings breakeven, he added.

“We believe that topicals are among the most attractive segments for an emerging generics company, with higher barriers to entry and better pricing,” he said. “We believe that this further makes IGI Labs a target for industry consolidation.”

Yahoo! Finance Worldwide

Quotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.